Zinc oxide fabricated by rutin as potent anti-leukemia nanostructure
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-024-03724-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Fatemeh Azizi Alidoust und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Faculty of Basic Sciences, Lahijan Branch, Islamic Azad University, Lahijan, Iran. Hauptthemen laut MEDLINE: Zinc Oxide, Rutin, Antineoplastic Agents, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Treatment of chronic myeloid leukemia (CML) is a significant therapeutic challenge, and exploration of novel treatment approaches is an urgent necessity. This work investigates the anticancer properties of rutin-conjugated zinc oxide nanoparticles (Rut-ZnO NPs) against CML cells. Physicochemical properties of the NPs were studied by FT-IR, FE-SEM, XRD, zeta potential, and DLS analyses. The MTT, flow cytometry, and quantitative PCR assays were utilized to evaluate cell viability, apoptosis, and Bax/Bcl-2 ratio, respectively. The ZnO-Rut NPs were amorphous with an average size of 59.50 nm, and hydrodynamic size and zeta potential were 161.7nm and -34.3 mV, respectively. The ZnO-Rut NPs showed good cytocompatibility as the viability of peripheral blood mononuclear cells remained above 85% at concentrations up to 100 μg/mL. ZnO-Rut NPs reduced the viability of K562 cells from 92 to 31% at exposure concentrations from 3.125 to 400 μg/mL. The IC50 values for rutin, ZnO NPs, and ZnO-Rutin NPs against K562 cells were 501.8, 386.3, and 175.9 μg/mL, respectively. Following the exposure to ZnO-Rutin NPs, the percentage of early apoptosis increased slightly from 10.5% to 14.1%, and a significant increase (from 11% to 50.9%) in late apoptosis was observed. The mRNA level of the Bax elevated to 1.98 folds, and the Bcl-2 gene was downregulated to 0.33 folds, underscoring the mechanism by which ZnO-Rutin NPs promote apoptosis. This study highlights the efficient anticancer potential of ZnO-Rutin NPs against CML cells, providing the basis for further investigations into their clinical applicability and underlying mechanisms of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Faculty of Basic Sciences, Lahijan Branch, Islamic Azad University, Lahijan, Iran.
- Department of Microbiology, Faculty of Basic Sciences, Lahijan Branch, Islamic Azad University, Lahijan, Iran. behnam.rasti@iau.ac.ir.
- Department of Biology, University of Guilan, Rasht, Iran. h_zamani@guilan.ac.ir.
- Department of Biology, Parand Branch, Islamic Azad University, Parand, Iran.
Zitieren
APA
Alidoust, F. A., Zahmatkesh, H., Rasti, B., Zamani, H., Mirpour, M., & Mirzaie, A. (2025). Zinc oxide fabricated by rutin as potent anti-leukemia nanostructure. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03724-1
Vancouver
Alidoust FA, Zahmatkesh H, Rasti B, Zamani H, Mirpour M, Mirzaie A. Zinc oxide fabricated by rutin as potent anti-leukemia nanostructure. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03724-1
BibTeX
@article{Alidoust2025,
author = {Alidoust, Fatemeh Azizi and Zahmatkesh, Hossein and Rasti, Behnam and Zamani, Hojjatolah and Mirpour, Mirsasan and Mirzaie, Amir},
title = {Zinc oxide fabricated by rutin as potent anti-leukemia nanostructure},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-024-03724-1}
}
EUVIMED